ResMed (NYSE: RMD) CFO sells 1,000 shares in Rule 10b5-1 trade

Rhea-AI Filing Summary

ResMed Inc.'s Chief Financial Officer Brett Sandercock sold 1,000 shares of ResMed common stock in an open‑market transaction at $254.30 per share on March 2, 2026. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 19, 2025, and he now holds 84,495 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	03/02/2026		S(1)		1,000	D	$254.3	84,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

	/s/ Brett Sandercock, Chief Financial Officer	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed (RMD) report for Brett Sandercock?

ResMed reported that CFO Brett Sandercock sold 1,000 shares of ResMed common stock. The open‑market sale occurred on March 2, 2026 at $254.30 per share under a pre‑arranged Rule 10b5‑1 trading plan.

At what price did ResMed (RMD) CFO sell his shares?

ResMed’s CFO sold 1,000 shares at $254.30 per share. This open‑market transaction on March 2, 2026 was executed pursuant to a Rule 10b5‑1 trading plan adopted on February 19, 2025.

How many ResMed (RMD) shares does the CFO hold after this sale?

After selling 1,000 shares, ResMed’s CFO Brett Sandercock directly holds 84,495 shares of ResMed common stock. This remaining ownership is reported in the Form 4 as the total shares beneficially owned following the transaction.

Was the ResMed (RMD) CFO’s share sale under a Rule 10b5-1 plan?

Yes, the CFO’s 1,000‑share sale was conducted under a Rule 10b5‑1 trading plan. The plan was adopted on February 19, 2025, allowing pre‑scheduled trades independent of day‑to‑day market developments or subsequent insider information.

What type of transaction did the ResMed (RMD) Form 4 disclose?

The Form 4 disclosed a sale of ResMed common stock in the open market. The transaction code was “S,” indicating a sale, and it involved 1,000 shares at $254.30 per share by the company’s Chief Financial Officer.